Atorlip 10: Effective LDL Cholesterol Management for Cardiovascular Health
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.70 | $94.60 $83.42 (12%) | 🛒 Add to cart |
| 180 | $0.66 | $141.90 $119.54 (16%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.86 (19%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $283.80 $227.04 (20%) | 🛒 Add to cart |
Atorlip 10 is a prescription medication containing atorvastatin calcium, a potent lipid-lowering agent belonging to the statin class. It is specifically formulated to reduce elevated levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B, while moderately increasing high-density lipoprotein (HDL) cholesterol. Clinical evidence supports its role in primary and secondary prevention of cardiovascular events, including myocardial infarction and stroke, in appropriate patient populations. This medication requires healthcare supervision and adherence to prescribed lifestyle modifications for optimal therapeutic outcomes.
Features
- Active ingredient: Atorvastatin calcium 10 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Competitive inhibitor of HMG-CoA reductase
- Bioavailability: Approximately 12%
- Protein binding: ≥98%
- Elimination half-life: Approximately 14 hours
- Metabolism: Hepatic via CYP3A4
- Excretion: Primarily biliary; <2% renal excretion
Benefits
- Significantly reduces LDL cholesterol levels by 35–50% at the 10 mg dose
- Lowers risk of major cardiovascular events in patients with established heart disease
- Decreases triglyceride levels and modestly raises HDL cholesterol
- Provides plaque stabilization and regression in coronary arteries
- Offers convenient once-daily dosing for improved adherence
- Supported by extensive clinical trial data demonstrating long-term safety profile
Common use
Atorlip 10 is indicated as an adjunct to diet for the reduction of elevated total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolemia and mixed dyslipidemia. It is also approved for homozygous familial hypercholesterolemia and to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina in adult patients with multiple risk factors but without clinically evident coronary heart disease. The medication is commonly prescribed for both primary prevention in high-risk individuals and secondary prevention in patients with established cardiovascular disease.
Dosage and direction
The recommended starting dose is 10 mg or 20 mg once daily. Patients requiring large LDL cholesterol reductions (>45%) may start at 40 mg daily. The dosage range is 10–80 mg daily. Administration can occur at any time of day, with or without food. Dosage adjustments should be made at intervals of 2–4 weeks based on lipid-level response and tolerability. For patients taking cyclosporine, clarithromycin, itraconazole, or certain HIV protease inhibitors, the dose should not exceed 10 mg daily. Renal impairment does not typically require dosage adjustment, while hepatic impairment may necessitate caution and possible dosage reduction.
Precautions
Liver function tests should be performed before initiation and periodically during treatment. Patients should report unexplained muscle pain, tenderness, or weakness promptly. Caution is advised in patients consuming substantial quantities of alcohol or with history of liver disease. Blood glucose levels should be monitored as statins may increase HbA1c and fasting serum glucose levels. The medication should be used cautiously in elderly patients and those with predisposing factors for rhabdomyolysis. Patients should be advised about the potential for cognitive impairment, though typically reversible upon discontinuation.
Contraindications
Atorlip 10 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. It must not be used during pregnancy or breastfeeding due to potential fetal harm and decreased cholesterol synthesis. Contraindications include hypersensitivity to any component of the formulation and concomitant use with strong CYP3A4 inhibitors in patients requiring doses above 20 mg. The medication is also contraindicated in women of childbearing potential not using adequate contraception.
Possible side effects
Common adverse reactions (≥2%) include: arthralgia, diarrhea, dyspepsia, nausea, increased liver enzymes, musculoskeletal pain, and insomnia. Less frequent but serious side effects may include: myopathy/rhabdomyolysis with potential renal impairment, hepatotoxicity, increased HbA1c and fasting serum glucose levels, and cognitive impairment (memory loss, confusion). Rare cases of immune-mediated necrotizing myopathy, hemorrhagic stroke, and tendon disorders have been reported. Most side effects are mild to moderate and often resolve with continued therapy or dosage adjustment.
Drug interaction
Significant interactions occur with strong CYP3A4 inhibitors: clarithromycin, itraconazole, HIV protease inhibitors—concomitant use requires maximum 10 mg dose. Moderate CYP3A4 inhibitors: diltiazem, verapamil—consider dose reduction. Gemfibrozil and other fibrates increase rhabdomyolysis risk. Warfarin: monitor INR closely. Oral contraceptives: increased hormone levels. Digoxin: monitor concentrations. Colchicine: increased myopathy risk. Calcium channel blockers: possible increased statin exposure. Antacids: decreased atorvastatin absorption—separate administration by at least 2 hours.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Consistent daily administration is important for maintaining stable lipid-lowering effects. Patients should be educated about establishing a routine (e.g., taking with a daily meal or at bedtime) to improve adherence and minimize missed doses.
Overdose
There is no specific antidote for atorvastatin overdose. Suspected overdose should involve supportive measures including gastric lavage if presented early. Liver function tests and CPK levels should be monitored. Rhabdomyolysis and acute renal failure are potential complications requiring appropriate management. Hemodialysis is not expected to significantly enhance elimination due to extensive protein binding. Symptomatic treatment should be provided based on clinical manifestations. Medical toxicology consultation is recommended for significant overdoses.
Storage
Store at room temperature (15–30°C) in the original container protected from light and moisture. Keep tightly closed and away from excessive heat or humidity. Do not store in bathroom cabinets where moisture levels fluctuate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication through take-back programs is recommended to prevent accidental ingestion or environmental contamination.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Atorlip 10 is a prescription medication that should only be used under appropriate medical supervision. Healthcare professionals should reference the full prescribing information before initiating therapy. Patients must consult their physician for personalized medical advice, diagnosis, and treatment. Individual responses to medication may vary based on genetic factors, comorbidities, and concomitant medications.
Reviews
Clinical studies demonstrate Atorlip 10 mg effectively reduces LDL cholesterol by 35–50% in most patients. The TNT trial showed significant cardiovascular risk reduction with atorvastatin therapy. Real-world evidence supports good tolerability profile with discontinuation rates due to adverse effects typically below 5%. Most patients report satisfactory lipid control with the 10 mg dose, though some require titration to higher doses for optimal response. Healthcare providers note improved adherence with once-daily dosing compared to older statins requiring multiple daily doses.